Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 6/20 | 0.48 |
| ▸ | DHODH | Q02127 | 8/20 | 0.41 |
| ▸ | THRA | P10827 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 2/20 | 0.41 |
| ▸ | S1PR4 | O95977 | 3/20 | 0.41 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL207683 | 0.85 | S1PR1 (0.49) | S1PR1THRATHRBS1PR4S1PR5 | |
| SCHEMBL2697754 | 0.81 | DHODH (0.53) | S1PR1DHODHTHRATHRBS1PR4 | |
| SCHEMBL3124573 | 0.80 | CHRNA7 (0.52) | S1PR1DHODHTHRATHRBS1PR4 | |
| SCHEMBL3129516 | 0.79 | S1PR1 (0.48) | S1PR1THRATHRBS1PR4S1PR5 | |
| SCHEMBL3131366 | 0.78 | S1PR1 (0.44) | S1PR1DHODHTHRATHRBS1PR4 | |
| SCHEMBL207445 | 0.77 | S1PR1 (0.43) | S1PR1DHODHTHRATHRBS1PR4 | |
| SCHEMBL205677 | 0.77 | S1PR1 (0.43) | S1PR1DHODHTHRATHRBS1PR4 | |
| SCHEMBL206523 | 0.77 | S1PR1 (0.53) | S1PR1THRATHRBS1PR4S1PR5 | |
| SCHEMBL206224 | 0.77 | S1PR1 (0.54) | S1PR1THRATHRBS1PR4S1PR5 | |
| SCHEMBL208285 | 0.76 | DHODH (0.42) | S1PR1DHODHTHRATHRBS1PR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183263-B2 | Heteroaryl substituted thiazoles | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-8183263-B2 | Heteroaryl substituted thiazoles | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-8183263-B2 | Heteroaryl substituted thiazoles | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-20090041720-A1 | HETEROARYL SUBSTITUTED THIAZOLES | ACHILLION PHARMACEUTICALS, INC. (US) | 2009-02-12 | — | — | US | disclosed |
| US-20090041720-A1 | HETEROARYL SUBSTITUTED THIAZOLES | ACHILLION PHARMACEUTICALS, INC. (US) | 2009-02-12 | — | — | US | disclosed |
| US-20090041720-A1 | HETEROARYL SUBSTITUTED THIAZOLES | ACHILLION PHARMACEUTICALS, INC. (US) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090041720-A1 | HETEROARYL SUBSTITUTED THIAZOLES | CYP3A43, CYP3A7, HAVCR2 | S1PR1 3564/4885DHODH 667/4885THRA 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.